CIK 0001787306
ARQT Arcutis Biotherapeutics, Inc.
Insider trading from SEC Form 4. Last filing Dec 31, 2024.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
6
with a Form 4 at this company
Signals
Open-market buys and sells at Arcutis Biotherapeutics, Inc., scored.
| Score | Side | Insider | Value | Shares | Holdings change | Price context | Filed |
|---|---|---|---|---|---|---|---|
| 3Weak | sell 210b5-1 | Burnett Patrick See Remarks | $24k | 1,691 | -1% | - | |
| 16Weak | sell 210b5-1 | Watanabe Todd Franklin See Remarks | $228k | 15,000 | -2% | - | |
| 18Weak | buy 2 | Watanabe Todd Franklin See Remarks | $21k | 6,038 | +1% | - | |
| 21Weak | sell 310b5-1 | Welgus Howard G. director | $125k | 10,000 | -6% | - | |
| 23Weak | buy 2 | Matsuda Masaru See Remarks | $19k | 5,657 | +3% | - | |
| 10Weak | buy | Edwards Larry Todd See Remarks | $7,767 | 1,093 | +1% | - | |
| 31Weak | sell 4 | Burnett Patrick See Remarks | $163k | 16,023 | -11% | - | |
| 10Weak | sell 410b5-1 | Matsuda Masaru See Remarks | $17k | 1,775 | -1% | - | |
| 46Moderate | sell 5 | Burnett Patrick See Remarks | $713k | 69,226 | -39% | - | |
| 50Moderate | sell 5 | Curran Terrie director | $94k | 8,687 | -46% | - | |
| 21Weak | sell 510b5-1 | Burnett Patrick See Remarks | $134k | 15,441 | -8% | - | |
| 19Weak | sell 510b5-1 | Welgus Howard G. director | $87k | 10,000 | -5% | - | |
| 20Weak | sell 510b5-1 | Watanabe Todd Franklin See Remarks | $120k | 13,871 | -2% | - | |
| 16Weak | sell 510b5-1 | Matsuda Masaru See Remarks | $44k | 5,015 | -3% | - |
Congressional trades
3 trades in ARQT disclosed by members of Congress under the STOCK Act. All congressional trades.
| Member | Type | Asset | Amount | Traded | Filed |
|---|---|---|---|---|---|
| Gilbert Ray Cisneros, Jr. House · D-CA | Purchase | ARQT Arcutis Biotherapeutics, Inc. - Common stock | $1,001 to $15k | May 29, 2026 | 10 days after the trade |
| Gilbert Ray Cisneros, Jr. House · D-CA | Purchase | ARQT Arcutis Biotherapeutics, Inc. - Common stock | $1,001 to $15k | Mar 3, 2026 | 35 days after the trade |
| Gilbert Ray Cisneros, Jr. House · D-CA | Partial sale | ARQT Arcutis Biotherapeutics, Inc. - Common stock | $1,001 to $15k | Dec 11, 2025 | 32 days after the trade |
Transactions
The last 25 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 31, 2024 | Burnett Patrick See Remarks | SOpen-market sale Common Stock10b5-1 | -1,691 | $14.00 | $24k | 126,978 | Dec 31, 2024 |
| Dec 20, 2024 | Watanabe Todd Franklin See Remarks | SOpen-market sale Common Stock10b5-1 | -15,000 | $15.17 | $228k | 823,430 | Dec 23, 2024 |
| May 31, 2024 | Matsuda Masaru See Remarks | POpen-market purchase Common Stock | +4,000 | $1.69 | $6,768 | 185,373 | Dec 3, 2024 |
| May 31, 2024 | Watanabe Todd Franklin See Remarks | POpen-market purchase Common Stock | +4,000 | $1.69 | $6,768 | 836,392 | Dec 3, 2024 |
| Nov 30, 2024 | Edwards Larry Todd See Remarks | POpen-market purchase Common Stock | +1,093 | $7.11 | $7,767 | 137,728 | Dec 3, 2024 |
| Dec 2, 2024 | Welgus Howard G. director | SOpen-market sale Common Stock10b5-1 | -10,000 | $12.51 | $125k | 161,944 | Dec 3, 2024 |
| Nov 30, 2024 | Matsuda Masaru See Remarks | POpen-market purchase Common Stock | +1,657 | $7.11 | $12k | 187,030 | Dec 3, 2024 |
| Nov 30, 2024 | Watanabe Todd Franklin See Remarks | POpen-market purchase Common Stock | +2,038 | $7.11 | $14k | 838,430 | Dec 3, 2024 |
| Nov 22, 2024 | Burnett Patrick See Remarks | MOption exercise Common Stock | +16,023 | $0.00 | $0 | 144,692 | Nov 26, 2024 |
| Nov 22, 2024 | Burnett Patrick See Remarks | SOpen-market sale Common Stock | -16,023 | $10.14 | $163k | 128,669 | Nov 26, 2024 |
| Nov 22, 2024 | Burnett Patrick See Remarks | MOption exercise Stock Option (right to buy)derivative | -16,023 | $0.00 | $0 | 218,500 | Nov 26, 2024 |
| Nov 18, 2024 | Matsuda Masaru See Remarks | AGrant or award Common Stock10b5-1 | +4,875 | $0.00 | $0 | 183,148 | Nov 19, 2024 |
| Nov 19, 2024 | Matsuda Masaru See Remarks | SOpen-market sale Common Stock10b5-1 | -1,775 | $9.68 | $17k | 181,373 | Nov 19, 2024 |
| Nov 14, 2024 | Burnett Patrick See Remarks | SOpen-market sale Common Stock | -50,749 | $10.29 | $522k | 128,669 | Nov 18, 2024 |
| Nov 14, 2024 | Burnett Patrick See Remarks | MOption exercise Common Stock | +18,377 | $0.00 | $0 | 147,046 | Nov 18, 2024 |
| Nov 14, 2024 | Burnett Patrick See Remarks | SOpen-market sale Common Stock | -18,377 | $10.29 | $189k | 128,669 | Nov 18, 2024 |
| Nov 15, 2024 | Burnett Patrick See Remarks | MOption exercise Common Stock | +100 | $0.00 | $0 | 128,769 | Nov 18, 2024 |
| Nov 15, 2024 | Burnett Patrick See Remarks | SOpen-market sale Common Stock | -100 | $10.03 | $1,003 | 128,669 | Nov 18, 2024 |
| Nov 14, 2024 | Burnett Patrick See Remarks | MOption exercise Stock Option (right to buy)derivative | -18,377 | $0.00 | $0 | 234,623 | Nov 18, 2024 |
| Nov 15, 2024 | Burnett Patrick See Remarks | MOption exercise Stock Option (right to buy)derivative | -100 | $0.00 | $0 | 234,523 | Nov 18, 2024 |
| Nov 11, 2024 | Curran Terrie director | SOpen-market sale Common Stock | -8,687 | $10.85 | $94k | 10,139 | Nov 13, 2024 |
| Nov 4, 2024 | Burnett Patrick See Remarks | SOpen-market sale Common Stock10b5-1 | -15,441 | $8.68 | $134k | 179,418 | Nov 5, 2024 |
| Nov 4, 2024 | Watanabe Todd Franklin See Remarks | SOpen-market sale Common Stock10b5-1 | -13,871 | $8.68 | $120k | 832,392 | Nov 5, 2024 |
| Nov 4, 2024 | Matsuda Masaru See Remarks | SOpen-market sale Common Stock10b5-1 | -5,015 | $8.68 | $44k | 178,273 | Nov 5, 2024 |
| Nov 1, 2024 | Welgus Howard G. director | SOpen-market sale Common Stock10b5-1 | -10,000 | $8.65 | $87k | 171,944 | Nov 5, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Burnett PatrickSee Remarks
- Curran Terriedirector
- Edwards Larry ToddSee Remarks
- Matsuda MasaruSee Remarks
- Watanabe Todd FranklinSee Remarks
- Welgus Howard G.director
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.